Eamon N. Dreisbach

WAILEA, Hawaii — When making treatment decisions for geographic atrophy, atrophy geometry, lesion size and focality are some of the features that must be considered, according to a speaker here.

Aura Biosciences announced that it has received an agreement from the FDA under a special protocol assesment for the design of a phase 3 trial assessing belzupacap sarotalocan, according to a press release.

SAN FRANCISCO — A low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children aged 3 to 17 years, according to phase 3 data presented here.

SAN FRANCISCO — When administering anti-VEGF treatments to patients with wet age-related macular degeneration, diabetic macular edema or retinal vein occlusion who have severe glaucoma, be mindful of the speed and volume of injections.

SAN FRANCISCO —The global ophthalmic market was worth an estimated $48.5 billion in 2023, according to Market Scope data presented here.

SEATTLE — Chronic and recurrent uveitis requires chronic treatment, according to a speaker here.

SEATTLE — At the American Society of Retina Specialists annual meeting, the ReST Committee shared an update on intraocular inflammation reported in patients who received Syfovre.

KOLOA, Hawaii — Artificial intelligence has the potential to help ophthalmologists better perform clinical exams, as well as diagnose and classify disease, according to a speaker here.

KOLOA, Hawaii — Ultra-widefield fluorescein angiography may enable more sensitive and specific methods to predict diabetic retinopathy worsening compared with standard FA, Paolo S. Silva, MD, said at Retina 2023.

KOLOA, Hawaii — When deciding which patients with diabetic retinopathy to treat with anti-VEGFs, ophthalmologists should consider severity of disease, according to a speaker here.